Nucleus accumbens pathways control cell-specific gene expression in the medial prefrontal cortex

Takatoshi Hikida1,2,9*, Shuhei Yao3,9, Tom Macpherson1,2,9, Ayumi Fukakusa3, Makiko Morita1,2, Haruhide Kimura3, Keisuke Hirai3, Tatsuya Ando3, Hiroyoshi Toyoshiba3 & Akira Sawa4,5,6,7,8

The medial prefrontal cortex (mPFC) is a critical component of a cortico-basal ganglia-thalamo-cortical loop regulating limbic and cognitive functions. Within this circuit, two distinct nucleus accumbens (NAc) output neuron types, dopamine D1 or D2 receptor-expressing neurons, dynamically control the flow of information through basal ganglia nuclei that eventually project back to the mPFC to complete the loop. Thus, chronic dysfunction of the NAc may result in mPFC transcriptomal changes, which in turn contribute to disease conditions associated with the mPFC and basal ganglia. Here, we used RNA sequencing to analyse differentially expressed genes (DEGs) in the mPFC following a reversible neurotransmission blocking technique in D1 or D2 receptor-expressing NAc neurons, respectively (D1-RNB, or D2-RNB). Gene Set Enrichment Analysis revealed that gene sets of layer 5b and 6 pyramidal neurons were enriched in DEGs of the mPFC downregulated in both NAc D1- and D2-RNB mice. In contrast, gene sets of layer 5a pyramidal neurons were enriched in upregulated DEGs of the mPFC in D1-RNB mice, and downregulated DEGs of the mPFC in D2-RNB mice. These findings reveal for the first time that NAc output pathways play an important role in controlling mPFC gene expression.
**Results**

**EdgeR and voom gene expression analysis of the mPFC after NAc D1-MSN or D2-MSN pathway inhibition.** Two methods, edgeR and voom, were applied to gene expression data and DEGs were individually identified. After comparing mPFC samples from D1-RNB mice with those from WT controls, edgeR and voom identified DEGs were significantly overlapped for 707 up-regulated genes (Fig. 1; \(-\log P = 2093.32\)) and 189 down-regulated genes (Fig. 1; \(-\log P = 780.94\)). Whereas, in the mPFC samples of D2-RNB mice compared with WT controls, edgeR and voom identified DEGs were significantly overlapped for 175 up-regulated genes (Fig. 1; \(-\log P = 753.31\)) and 92 down-regulated genes (Fig. 1; \(-\log P = 427.43\)). Of these DEGs identified by both edgeR and voom methods, only 25 up-regulated genes (\(-\log P = 15.59\)) and 9 down-regulated genes (\(-\log P = 15.32\)) were shared by both D1-RNB and D2-RNB mice. Only one gene, Gpr88, was observed to be down-regulated in NAc D1-RNB mice and up-regulated in NAc D2-RNB mice, and is known to be a modulator of the striatal dopamine system.

After normalization (see Methods), hierarchical clustering of the expression profile of 1163 robust DEGs in the mPFC was performed to investigate whether gene expression patterns were similar within genotypes and different between genotypes. With the exception of one D1-RNB sample, the expression profiles for all 1163 DEGs were clustered into three groups corresponding to each genotype (x axis in Supplementary Fig. S1). Additionally, within these groups, four distinct clusters were identified, corresponding to the groups of DEGs up-regulated or...
Enrichment of gene sets related to neurological diseases in the mPFC of NAc D1-RNB and D2-RNB mice. To evaluate whether robust DEGs in the mPFC are associated with disease-related functions, functional enrichment analysis by IPA was performed. Down-regulated DEGs in the mPFC of D1-RNB mice were found to be significantly overlapped with gene sets functionally related with disorders associated with impaired motor control, including “dyskinesia” \((p = 1.96E-03)\), “Huntington’s disease” \((p = 2.52E-03)\), and “neuromuscular disorder” \((p = 2.61E-03)\), as well as with “primary insomnia” \((p = 7.14E-04)\), and developmental disorders associated with impaired cognition, including “autism” \((p = 1.58E-03)\) and “attention deficit hyperactivity disorder” \((p = 2.25E-03)\) (Table 1). Up-regulated DEGs in the mPFC of D2-RNB mice were similarly found to be overlapped with gene sets related to several disorders associated with impaired motor control, including “Movement disorders” \((p = 5.63E-06)\), “neuromuscular disease” \((p = 2.65E-05)\), “Huntington’s disease” \((p = 1.19E-05)\), and “cataplectic” \((p = 1.79E-04)\), as well as with gene sets functionally associated with “sleep disorders” \((p = 1.59E-04)\) and “cocaine-related disorder” \((p = 3.30E-06)\) (Table 2). These findings confirm that chronic inhibition of signalling in NAc D1- and D2-MSNs alters mPFC expression of genes associated with disorders of the mPFC-basal ganglia-thalamo-mPFC circuit.

Estimation of CNS cell types altered by NAc D1-RNB and D2-RNB. The GSEA computational method was used to calculate the degree to which the expression patterns of a priori defined gene sets for specific cell types were altered by chronic neurotransmission blocking of NAc D1- or D2-MSNs. GSEA using gene sets identified from TRAP data from 25 CNS cell types (Table 3) was performed separately on the full datasets for edgeR and voom to investigate potential cell types in the mPFC contributing to differences between NAc D1-RNB and D2-RNB. Of 10 cortical cell types, gene sets for mature oligodendrocytes (Ctx.Cmtm5) (Fig. 2; D1-RNB; edgeR \(p < 1.0E-03\), voom \(p < 1.0E-03\), D2-RNB; edgeR \(p < 1.0E-03\), voom \(p < 1.0E-03\), D2-RNB; edgeR \(p < 1.0E-03\), voom \(p < 1.0E-03\)), mixed oligodendroglia (Ctx.Olig) (Fig. 2; D1-RNB; edgeR \(p < 1.0E-03\), voom \(p < 1.0E-03\), D2-RNB; edgeR \(p < 6.7E-03\), voom \(p = 3.6E-03\), and astrocytes (Ctx.AldhL1) (Fig. 2; D1-RNB; edgeR \(p < 1.0E-03\), voom \(p < 1.0E-03\), D2-RNB; edgeR \(p = 0.19\), voom \(p = 0.081\)) were found to be significantly enriched in genes up-regulated in the mPFC of both D1- and D2-RNB mice, indicating that chronic blockade of neurotransmission in NAc D1- and D2-MSN pathways results in increased expression genes associated with several types of glial cells within the mPFC.

Of cortical neuron gene sets, gene sets for Glt25d2- (Ctx.Glt25d2) and Ntsr1-expressing (Ctx.Ntsr1) neurons, previously identified to be layer 5b and layer 6 pyramidal neurons, respectively\(^{20,22}\), were enriched in genes down-regulated by both NAc D1-RNB (Fig. 2; Ctx.Glt25d2: edgeR \(p = 9.3E-03\), voom \(p < 1.0E-03\), Ctx.Ntsr1: edgeR \(p = 1.1E-02\), voom \(p = 0.01\)) and NAc D2-RNB (Fig. 2; Ctx.Glt25d2: edgeR \(p < 1.0E-03\), voom \(p < 1.0E-03\), Ctx.Ntsr1: edgeR \(p = 2.9E-03\), voom \(p = 2.2E-03\)). Additionally, gene sets for cell types previously identified to be layer 5a pyramidal neurons\(^{19,20}\) were revealed to be enriched in genes up-regulated in the mPFC of NAc D1-RNB mice (Ctx.S100a10 gene set only) (Fig. 2; Ctx.S100a10: edgeR \(p = 3.1E-03\), voom \(p = 0.013\)) and down-regulated in the mPFC of D2-RNB mice (both Ctx.S100a10 and Ctx.Etv1 gene sets) (Fig. 2; Ctx.S100a10: edgeR \(p < 1.0E-03\), voom \(p = 2.1E-03\), Ctx.Etv1: edgeR \(p = 3.2E-03\), voom \(p < 1.0E-03\)). Thus, chronic neurotransmission blocking of NAc D1- and D2-MSN pathways reduces the expression of both layer 5b and Layer 6 pyramidal neuron-related genes, but increases or decreases, respectively, the expression of layer 5a pyramidal neuron-related genes. The complete set of results for the 25 cell types are shown in Supplementary Fig. S2.

S100a10-expressing layer 5a pyramidal neuron-related gene expression differs in the mPFC of NAc D1-RNB and NAc D2-RNB mice. Given that gene set for S100a10-expressing layer 5a pyramidal neurons (Ctx.S100a10) was enriched in both genes up-regulated in the mPFC of D1-RNB mice and down-regulated in the mPFC of D2-RNB mice, we investigated whether opposing patterns of expression were occurring in the same genes. The five most up-regulated genes in the Ctx.S100a10 gene set in mPFC samples of NAc D1-RNB mice (Fig. 3A) were found to differ from the five most down-regulated genes in the gene set in mPFC samples of NAc D2-RNB mice (Fig. 3B). Thus, while chronic neurotransmission blocking of NAc D1- and D2-MSN produced a general bidirectional effect on the expression of genes within this layer 5a pyramidal neuron gene set, the degree to which the expression of individual genes within this gene set was bidirectionally controlled differed.

Discussion

The mPFC and NAc form critical components of an mPFC-basal ganglia-thalamo-mPFC loop circuit that is proposed to link cognition to action selection, and dysfunction of this circuit has been suggested to contribute to several neuropsychopathologies associated with impaired cognitive function and behavioural control\(^{11,12,31-34}\). Here, for the first time, we reveal that blocking neurotransmission in NAc D1- or D2-MSNs was able to alter the mPFC transcriptome, producing different patterns of gene expression within specific cell types in the mPFC (see Fig. 4). Up-regulated or down-regulated genes in the mPFC showed little overlap between D1- and D2-RNB groups, and gene expression profiles could be hierarchically clustered into three groups corresponding to each genotype. This would suggest that similar to their distinct roles in controlling various forms of learning and behaviour, NAc D1- and D2-MSNs also have largely divergent influences on gene expression within the mPFC. Further investigation using ingenuity pathway analysis revealed that mPFC genes down-regulated by NAc D1-RNB and up-regulated by NAc D2-RNB significantly overlapped with several gene sets functionally associated with developmental and psychiatric disorders characterized by impaired cognition, as well as with gene sets for movement-related disorders. Many of these overlapped genes were present in multiple gene sets and were responsible for diverse and important roles throughout the brain, including encoding for several types of receptors, enzymes, and monoamine transporters. However, it is still unclear whether transcriptional changes in the mPFC

3
result in altered expression of proteins, and further research is warranted to investigate whether potential translational alterations contribute to functional impairments associated with chronic inhibition of signalling in NAc D1- and D2-MSNs, including behavioural and learning dysfunctions.

GSEA using gene sets for cortical cell types revealed that chronic blockade of neurotransmission in NAc D1- and D2-MSN pathways results in increased mPFC expression of genes associated with several types of glial cells, including mature oligodendrocytes, mixed oligodendroglia, and astrocytes. Given the diverse functions of glial cells, the enrichment of these gene sets may produce a considerable influence on mPFC function, and further investigation of the consequences of gene expression up-regulation in glial cells is necessary.

Of cortical neuron groups, gene expression in gene sets for layer 5b and 6 pyramidal neuron-types was found to be significantly down-regulated in the mPFC of both D1-RNB and D2-RNB mice. Previous studies using BAC Cre-recombinase driver lines to study these neuron types have revealed that Gltd25d2-expressing layer 5b pyramidal neurons project to areas of the lateral dorsal and lateral posterior thalamic nuclei, the striatum, and the pontine nuclei, while Ntsr1-expressing layer 6 pyramidal neurons project largely to the dorsal thalamic nuclei. Interestingly, the gene sets for layer 5a pyramidal neurons were revealed to be bidirectionally enriched in the mPFC following blockade of neurotransmission in NAc pathways, with NAc D1-RNB resulting in increased expression of genes in the gene set for S100a10-expressing neurons, and NAc D2-RNB resulting in

| Function | p-value | Genes | Number of genes |
|----------|---------|-------|-----------------|
| Primary insomnia | 7.14E-04 | GABRA5, GABRB2, HTR2A | 3 |
| Epileptic encephalopathy | 1.32E-05 | GABRA5, GABRB2, HCN1, HTR2A, NECAP1 | 5 |
| Neurological signs | 1.47E-03 | ATPT6V1A, CETN2, CHN1, CRYM, FBXW7, FDF1, FLRT2, GABRA5, GABRB2, GPR88, GUCY1B3, HSP90AA1, HSP48, HTR2A, HTR2B, MME, NPTX2, OPRM1, SGTB | 18 |
| Autism | 1.58E-03 | ALDH213, CAMP52, GABRA5, GABRB2, HTR2A | 5 |
| Dyskinesia | 1.96E-03 | ATPT6V1A, CETN2, CHN1, CRYM, FBXW7, FDF1, FLRT2, GABRA5, GABRB2, GPR88, GUCY1B3, HSP90AA1, HSP48, HTR2A, MME, NPTX2, OPRM1, SGTB | 17 |
| Ohtahara syndrome | 2.08E-03 | GABRA5, HCN1, HTR2A, NECAP1 | 4 |
| Attention deficit hyperactivity disorder | 2.25E-03 | GABRA5, GABRB2, HTR2A, OPRM1 | 4 |
| Huntington's Disease | 2.52E-03 | GABRA5, GABRB2, HCN1, HTR2A, NECAP1, SHGL2, SV2B | 16 |
| Seizure disorder | 2.60E-03 | CD83, CHN1, CRYM, ELAVL4, GABRA5, GABRB2, HCN1, HSP48, HTR2A, NECAP1, OPRM1, SHGL2, SV2B | 14 |
| Neuromuscular disease | 2.61E-03 | ATPT6V1A, C55, CETN2, CHN1, CRYM, FBXW7, FDF1, FLRT2, GABRA5, GABRB2, GPR88, GUCY1B3, HSP90AA1, HSP48, HTR2A, IFIT1, KCNA3, MDH1, OPRM1, SGTB, SHGL2 | 21 |

Table 1. Top 10 functions associated with down-regulated genes in the medial prefrontal following D1-RNB.

| Function | p-value | Genes | Number of genes |
|----------|---------|-------|-----------------|
| Disorders of the basal ganglia | 1.29E-06 | ADORA2A, API1A, CPT1B, DRD1, DRD2, DYNLT1, GPR6, GPR88, GRK1, IDO1, IL4, L1P1, L1P-NUDT1, PDE4C, PPP1R1B, PTGES3, RASGR2P, RG9, SCN9A, SLIC18A2, SPOCK3, SYNPR, TSC22D3 | 23 |
| Cocaine-related disorder | 3.30E-06 | ADORA2A, DRD1, DRD2, ESRI1, PDE4C, SLIC18A2 | 6 |
| Movement Disorders | 5.63E-06 | ARCR7, ADORA2A, API1S2, COMMD3-BM1, CPT1B, DRD1, DRD2, DYNLT1, EFHC1, GNB4, GPR6, GPR88, GRK1, IDO1, IL4, L1P1, L1P-NUDT1, PDE4C, PPP1R1B, PTGES3, RASGR2P, RG9, SCN9A, SLIC18A2, SPOCK3, SYNPR, TSC22D3 | 27 |
| Huntington's Disease | 1.19E-05 | ADORA2A, CPT1B, DRD1, DRD2, DYNLT1, GPR6, GPR88, GRK1, IDO1, IL4, L1P1, L1P-NUDT1, PDE4C, PPP1R1B, PTGES3, RASGR2P, RG9, SCN9A, SLIC18A2, SPOCK3, SYNPR, TSC22D3 | 18 |
| Neuromuscular disease | 2.65E-05 | ADORA2A, API1S2, CPT1B, DRD1, DRD2, DYNLT1, GPR6, GPR88, GRK1, IDO1, L1P1, PPP1R1B, RASGR2P, RG9, SCN9A, SLIC18A2, SPOCK3, SYNPR, TSC22D3 | 22 |
| Advanced idiopathic Parkinson disease | 7.71E-05 | DRD1, DRD2 | 2 |
| Idiopathic Parkinson disease | 1.05E-04 | ADORA2A, DRD1, DRD2 | 3 |
| Sleep Disorders | 1.59E-04 | ADORA2A, DRD1, DRD2, ESRI1, GLRA2, PDE4C | 6 |
| Catalepsy | 1.79E-04 | ADORA2A, DRD2, PPP1R1B | 3 |
| Huntington disease grade 0 Huntington's disease | 2.30E-04 | ADORA2A, DRD2 | 2 |

Table 2. Top 10 functions associated with up-regulated genes in the medial prefrontal following D2-RNB.
decreased expression of genes in the gene set for S100a10- and Etv1-expressing neurons. Similar tracing studies using Cre-recombinase driver lines have demonstrated these layer 5a pyramidal neurons project to both the NAc and the dorsomedial striatum (DMS)19,20.

mPFC layer 5a, 5b, and 6 pyramidal neurons are known to play critical roles in controlling learning and decision-making processes. Thalamic projections from mPFC layer 6 neurons (“modulator” efferents) and, to a lesser extent, layer 5b neurons (“driver” efferents conveying processed cortical information) have been suggested to act as a part of a higher-order thalamic relay projecting information back to cortical areas including the mPFC to facilitate learning24. Whereas, DMS-projecting mPFC corticostriatal neurons have recently been shown to act in parallel with sensorimotor corticostriatal neurons projecting from the motor cortex M1 to the dorsolateral striatum (DLS) to control the early stages of motor skill learning, but are disengaged during and after mastery of the skill, at which time M1-DLS corticostriatal neuron activity plays an important role in solidifying the behaviour25. These findings led to the suggestion that mPFC-DMS corticostriatal neurons control attention and act to promote behavioural flexibility during early learning when multiple strategies are being tested. Recent evidence that inactivation of either mPFC corticostriatal or corticothalamic neurons impairs performance in reversal learning tasks further highlights the importance of mPFC neurons in adaptively controlling learning26,27. Interestingly, our previous work has demonstrated that NAc D2-RNB mice show similar impairments in reversal learning tasks, suggesting that a cortico-basal ganglia-thalamo-cortical circuit incorporating NAc D2-MSNs may play an important role in the ability for behavioural flexibility23,28.

While here we identify several cell types in which gene expression was specifically altered, a limitation of the current study is that the functional consequences of these transcriptional changes are still unclear. Future studies using in-vivo imaging or electrophysiological techniques in BAC cre-recombinase driver lines will likely provide valuable information about how these transcriptional changes alter signalling within specific cortical neurons during tasks that typically engage these projection neurons, including reward-based and reversal learning tasks. If discovered, these cortical neuron signalling alterations may help to explain deficits in reward, aversive, and reversal learning tasks previously reported in NAc D1- and D2-RNB mice26,27. Additionally, further studies combining the use of BAC transgenic mouse lines expressing cre-recombinase in specific cell-types with cre-specific anterograde and retrograde viruses expressing fluorescent markers, will help confirm the efferent projections of several of the cell types described in this study, as well as their possible presence within cortico-basal ganglia-thalamo-cortical circuits.

Finally, a further use for these data could be to screen the location of action and mechanisms of new drugs that act to alter signalling within the mPFC-basal ganglia-thalamo-cortical circuit, as well as to compare against gene expression profiling of small molecule treatments for the purpose of repurposing existing drugs that may have undiscovered effects on gene regulation. For example, drugs resulting in up-regulation of genes in the layer 5a pyramidal neuron gene set in the mPFC may be producing their action by decreasing signalling within NAc

| Gene Set Name | Brain region | Description | Source (GSE No.) |
|---------------|--------------|-------------|-----------------|
| Bf.Chat       | Basal Forebrain | Cholinergic Neurons | GSE13379 |
| Bs.Chat       | Brainstem | Motor Neurons | GSE13379 |
| Cb.Aldh111    | Cerebellum | Astrocytes | GSE13379 |
| Cb.Cnttm5     | Cerebellum | Mature Oligodendrocytes | GSE13379 |
| Cb.Grm2       | Cerebellum | Golgi Neurons | GSE13379 |
| Cb.Grp        | Cerebellum | Unipolar Brush Neurons | GSE13379 |
| Cb.Lypd6      | Cerebellum | Stellate and Basket Neurons | GSE13379 |
| Cb.Neurod1    | Cerebellum | Granule Neurons | GSE13379 |
| Cb.Olig       | Cerebellum | Mixed Oligodendroglia | GSE13379 |
| Cb.Pep2       | Cerebellum | Purkinje Neuron | GSE13379 |
| Cb.Sept4      | Cerebellum | Bergmann Glia | GSE13379 |
| Cx.Chat       | Striatum | Cholinergic Neurons | GSE13379 |
| Cx.Dre1       | Striatum | Drd1 + Medium Spiny Neurons | GSE13379 |
| Cx.Dre2       | Striatum | Drd2 + Medium Spiny Neurons | GSE13379 |
| Ctx.Alph111   | Cortex | Astrocytes | GSE13379 |
| Ctx.Cck       | Cortex | Cck+ Neurons | GSE13379 |
| Ctx.Cnttm5    | Cortex | Mature Oligodendrocytes | GSE13379 |
| Ctx.Cort      | Cortex | Cort+ Neurons | GSE13379 |
| Ctx.Etv1      | Cortex | Layer 5a Pyramidal Neurons | GSE35766 |
| Ctx.Gil25d2   | Cortex | Layer 5b Pyramidal Neurons | GSE35766 |
| Ctx.Ntr1      | Cortex | Layer 6 Pyramidal Neurons | GSE35766 |
| Ctx.Olig      | Cortex | Mixed Oligodendroglia | GSE13379 |
| Ctx.Pnoc      | Cortex | Pnoc+ Neurons | GSE13379 |
| Ctx.S100a10   | Cortex | Layer 5a Pyramidal Neurons | GSE35766 |
| Sc.Chat       | Spinal Cord | Cholinergic Neurons | GSE13379 |

Table 3. Description of gene sets for 25 cell types analysed by GSEA.
Figure 2. GSEA estimation of altered cortex cell types in the mPFC by NAc D1-RNB/D2-RNB. Barplots indicate the GSEA-based normalized enrichment scores (NES) of cortical cell gene sets calculated by edgeR (left two panels) or voom (right two panels) for NAc D1-RNB vs WT (top two panels) and NAc D2-RNB vs WT (bottom two panels). X-axis: cortical cell types ordered by NES. Y-axis: NES are also displayed by colour gradient. Ctx.Aldh1l1; cortical astrocytes, Ctx.Cck; Cortical Cck+ neurons, Ctx.Cmtm5; cortical mature oligodendrocytes, Ctx.Cort; cortical Cort+ neurons, Ctx.Etv1; layer 5a pyramidal neurons, Ctx.Glt25d2; layer 5b pyramidal neurons, Ctx.Ntsr1; layer 6 pyramidal neurons, Ctx.Olig; cortical mixed oligodendroglia, Ctx. Pnoc; cortical Pnoc+ neurons, Ctx.S100a10; layer 5a pyramidal neurons.

Figure 3. S100a10-expressing layer 5a pyramidal neuron-related genes up- and down-regulated in the mPFC by D1-RNB and D2-RNB, respectively. (A) Percentage expression change from WT controls of the five most up-regulated genes in the S100a10-expressing layer 5a pyramidal neuron gene set in the mPFC of NAc D1-RNB mice, alongside WT and D2-RNB mice, as identified by voom. (B) Percentage expression change from WT controls of the five most down-regulated genes in the S100a10-expressing layer 5a pyramidal neuron gene set in the mPFC of NAc D2-RNB mice, alongside WT and D1-RNB mice, as identified by voom. Bars represent the mean percentage expression change from WTs ±SEM.
D1-MSNs. Similarly, in future, the gene expression patterns of specific mPFC cell types in NAc D1- and D2-RNB mice reported here could be compared with gene expression patterns in the same mPFC cell types of mouse models of psychiatric disorders associated with impaired mPFC function to help to identify how specific mPFC-basal ganglia-thalamo-mPFC pathways are altered in these conditions.

In conclusion, here, for the first time, we demonstrate that inhibition of NAc D1- and D2-MSNs produces similar or opposing changes in gene expression within specific mPFC cell types, and identify important mPFC cellular targets for future research into the role of NAc pathways in controlling the function of the mPFC-basal ganglia-thalamo-mPFC circuit (see Fig. 4). Further research is warranted to establish the functional influence of these transcriptomal changes on signalling within these mPFC cell types, and the extent to which these expression changes contribute to altered learning and behaviour reported in NAc D1- and D2-RNB mice.

Materials and Methods

Animal care. All recombinant mouse and viral experiment procedures were approved by the Institutional Safety Committee on Recombinant DNA Experiments (approval ID 04219), Animal Experimental Committee of Institute for Protein Research at Osaka University (approval ID 29-02-1), the Animal Care and Use Committee of Kyoto University (approval ID MedKyo17071). These procedures were performed under the institutional guidelines. Mice were housed in a temperature-controlled room at 22 °C with a 12 h light/dark cycle. Fresh water and rodent diet were available ad libitum.

Reversible neurotransmission blocking. A reversible neurotransmission blocking (RNB) technique was used to inhibit signalling in NAc D1- or D2-MSNs (D1-/D2-RNB), according to a previously described method8–10,23. Briefly, transgenic mice in which tetanus toxin light chain (TN) is expressed under the control of tetracycline-responsive element (TRE) received intra-NAc infusions one of two recombinant AAV viruses that express tetracycline transactivator (tTA) under a promotor for either Substance P (expressed in D1-MSNs) or Enkephalin (expressed in D2-MSNs) (AAV2-SP-tTA or AAV2-Enk-tTA; 500 nl/site at 100 nl/min; left for 5 min; coordinates: AP +1.4, L ±0.8 and DV −4.0 and −3.5). The interaction between the SP/ENK-expressed tTA and the TRE drives the release of neurotransmission blocking TN specifically in NAc D1- (SP) or D2- (Enk) MSNs, and is only reversed if doxycycline is administered. In the case of this study, mice were left with a permanent blockade of neurotransmission within NAc D1- or D2-MSNs.

RNA extraction and sequencing. Following cervical dislocation, freshly dissected brains were sliced into 1 mm-thick coronal sections using a mouse brain matrix. The medial prefrontal cortex (mPFC), identified using mouse brain atlas29, was dissected from brain slices using a 1.5 mm-diameter tissue puncher and frozen at −80 °C until the time of use. Total RNA were extracted from four mPFC samples from wild type (WT) mice, three mPFC samples from D1-RNB mice, and three mPFC samples from D2-RNB mice using the mirNeasy Mini Kit (QIAGEN, Hilden, Germany). The quality of purified RNA was assessed with an Experion™ Automated Electrophoresis Station using the Experion™ RNA StdSens Analysis Kit for mPFC (Bio-Rad Laboratories, CA, U.S.A.). RNA sequencing (RNA-seq) was conducted using Illumina HiSeq. 2000 in Beijing Genomics Institute (Hong Kong, China).
Statistical analysis of RNA-seq data. RNA-seq data were processed using Array Studio 8.0.0.78 (OmicSoft Corp., Cary, NC, U.S.A.) as follows. FASTQ files were mapped using mouse:mm10 as the reference library, and then gene annotations were added to the read count values with ensemblR76. After checking the mapping rate was over 85%, the read counts of all samples were exported. Statistical analysis was conducted by R language (https://www.r-project.org/). To identify mRNAs differentially expressed in the mPFC of D1-/D2-RNB and WT mice, the edgeR (empirical analysis of DGE in R) package30 and the voom (an acronym of “variance modeling at the observational level”) function in the limma package31 were applied. These are two major methods for calculation of RNA-Seq data set. To get robust differentially expressed genes, intersected genes by edgeR and voom were selected. For both edgeR and voom, only genes with a cpm value of more than 1 in at least one sample were kept for further analysis. Up- and down-regulated genes were identified by a p-value of less than 0.05 and a fold change of more than 1.2. Percentage expression change from WT controls for up-regulated and down-regulated genes was analysed using the averaged cpm for each group divided by the averaged cpm for the WT group and multiplied by 100. The top five up-regulated Ctx.S100a10-associated genes by D1-RNB and top five down-regulated Ctx.S100a10-associated genes by D2-RNB were analysed by univariate ANOVAs with the percentage expression change from WT controls as the dependent variable and genotype as the independent variable. Clustering of differentially expressed genes (DEGs) was conducted by spearman's correlation and an average method with R. A hypergeometric function was used to perform the enrichment analysis to compare DEGs by each method.

Enrichment analysis by ingenuity pathway analysis. The function of DEGs was investigated using Ingenuity Pathway Analysis (QIAGEN, Hilden, Germany) applied with a filter to capture only enriched gene sets related to “neurological diseases”, with the background gene set assigned to genes with a cpm > 1 for at least one comparison group.

Identification of CNS cell type-specific gene sets. A Specificity Index (SI) was used to identify gene sets specifically expressed in 25 CNS cell types (Table 3) isolated using TRAP (from Gene Expression Omnibus GSE13379 and GSE35766 data sets18,19). In the SI method, CEL files were processed by RMA using the Affy package. After normalization by quantile methods and transformation to log2 values, probes with values ≥ 25 percentile in at least 1 sample were extracted. To determine highly expressed genes in the isolated cells but not in the surrounding tissues, q-values < 0.05 and log2ratio > − 1 were applied as cut-offs for Welch's t-test. Using the SI calculated from the gene lists obtained by t-tests, gene lists for the enrichment analysis were produced using p < 0.01 against the data set.

Gene set enrichment analysis. Gene Set Enrichment Analysis (GSEA) was performed using java implementation GSEA software downloaded from the Broad Institute (http://www.broadinstitute.org/gsea) according to a previously described method25. Briefly, a normalized enrichment score (NES) is calculated for each gene set based upon the degree to which genes within the set are overrepresented at the extremes of a list of genes ranked by expression. Here, ranked gene lists as a query for GSEA were created separately from edgeR/voom data from D1-RNB/D2-RNB vs WT comparisons, rather than from the intersect list of "robust DEGs", due to the requirement of the full gene expression data set for GSEA.

Data availability
All RNA-Seq data sets generated and/or analysed during the current study were added to the Gene Expression Omnibus (GEO) under the accession number GSE124583.

Received: 4 July 2019; Accepted: 16 January 2020;
Published online: 04 February 2020

References
1. Albin, R., Young, A. & Penney, J. The functional anatomy of basal ganglia disorders. Trends in neurosciences 12, 366–375 (1989).
2. Alexander, G., DeLong, M. & Strick, P. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual review of neuroscience 9, 357–381 (1986).
3. Alexander, G. & Crutcher. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13, 266–271 (1990).
4. Haber, S. N. The primate basal ganglia: parallel and integrative networks. Journal of chemical neuroanatomy 26, 317–330 (2003).
5. Macpherson, T. & Hikida, T. Role of basal ganglia neurocircuitry in the pathology of psychiatric disorders. Psychiatry and clinical neuroscience 66, 636–375 (1989).
6. Macpherson, T. & Hikida, T. Striatal direct and indirect pathways control decision-making behavior. Frontiers in neuroscience 13, 266 (2019).
7. Sakurai, T. et al. Converging models of schizophrenia—Network alterations of prefrontal cortex underlying cognitive impairments. Progress in neurobiology 134, 178–201 (2015).
8. Hikida, T., Kimura, K., Wada, N., Funabiki, K. & Nakashiba, S. Distinct roles of synaptic transmission in direct and indirect striatal pathways to reward and aversive behavior. Neuron 68, 896–907 (2000).
9. Hikida, T. et al. Pathway-specific modulation of nucleus accumbens in reward and aversive behavior via selective transmitter receptors. Proceedings of the National Academy of Sciences of the United States of America 110, 342–347 (2013).
10. Macpherson, T. & Hikida, T. Nucleus Accumbens Dopamine D1-Receptor-Expressing Neurons Control the Acquisition of Sign-Tracking to Conditioned Cues in Mice. Frontiers in neuroscience 12, 418 (2018).
11. Macpherson, T., Morita, M. & Hikida, T. Striatal direct and indirect pathways control decision-making behavior. Frontiers in psychology 5, 1301 (2014).
12. Hikida, T., Morita, M. & Macpherson, T. Neural mechanisms of the nucleus accumbens circuit in reward and aversive learning. Neuroscience research 108, 1–5 (2016).
13. Kupchik, Y. M. et al. Coding the direct/indirect pathways by D1 and D2 receptors is not valid for accumbens projections. Nature neuroscience 18, 1230–1232 (2015).
14. Iemoto, S., Yang, C. & Tan, A. Basal ganglia circuit loops, dopamine and motivation: A review and enquiry. Behavioural brain research 290, 17–31 (2015).
24. Mitchell, A. S. The mediodorsal thalamus as a higher order thalamic relay nucleus important for learning and decision-making.
25. Kupferschmidt, D. A., Juczewski, K., Cui, G., Johnson, K. A. & Lovinger, D. M. Parallel, but Dissociable, Processing in Discrete
31. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts.
28. Yawata, S., Yamaguchi, T., Danjo, T., Hikida, T. & Nakanishi, S. Pathway-specific control of reward learning and its flexibility via
29. Paxinos, G. & Franklin, K. The Mouse Brain in Stereotaxic Coordinates (2013).
30. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene
20. Gong, S. et al. Targeting Cre Recombine to Specific Neuron Populations with Bacterial Artificial Chromosome Constructs. J
19. Schmidt, E. F. et al. Identification of the cortical neurons that mediate antidepressant responses. Cell 149, 1152–1163 (2012).
20. Gong, S. et al. Targeting Cre Recombine to Specific Neuron Populations with Bacterial Artificial Chromosome Constructs. J Neurosci 27, 9817–9823 (2007).
21. Logue, S. F. et al. The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders? Molecular and cellular neurosciences 42, 438–447 (2009).
22. Kim, E. J., Juvanet, A. L., Kyubwa, E. M., Jacobs, M. W. & Callaway, E. M. Three Types of Cortical Layer 5 Neurons That Differ in Brain-wide Connectivity and Function. Neuron 88, 1253–1267 (2015).
23. Macpherson, T. et al. Nucleus accumbens dopamine D2-receptor expressing neurons control behavioral flexibility in a place discrimination task in the IntelliCage. Learning & memory (Cold Spring Harbor, N.Y.) 23, 359–364 (2016).
24. Mitchell, A. S. The mediodorsal thalamus as a higher order thalamic relay nucleus important for learning and decision-making. Neurosci & Biobehavioral Reviews 54, 76–88 (2015).
25. Kupferschmidt, D. A., Juczewski, K., Cui, G., Johnson, K. A. & Lovinger, D. M. Parallel, but Dissociable, Processing in Discrete Corticostriatal Inputs Encodes Skill Learning. Neuron 96, 476–489.e5 (2017).
26. Ragozzino, M. E. The contribution of the medial prefrontal cortex, orbitofrontal cortex, and dorsomedial striatum to behavioral flexibility. Annals of the New York Academy of Sciences 1121, 355–375 (2007).
27. Nakayama, H., Ibahex-Tallon, I. & Heintz, N. Cell-Type-Specific Contributions of Medial Prefrontal Neurons to Flexible Behaviors. The Journal of neuroscience: the official journal of the Society for Neuroscience 38, 4490–4504 (2018).
28. Yawata, S., Yamaguchi, T., Danjo, T., Hikida, T. & Nakanishi, S. Pathway-specific control of reward learning and its flexibility via selective dopamine receptors in the nucleus accumbens. Proceedings of the National Academy of Sciences of the United States of America 109, 12764–12769 (2012).
29. Paxinos, G. & Franklin, K. The Mouse Brain in Stereotaxic Coordinates (2013).
30. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (Oxford, England) 26, 139–140 (2010).
31. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome biology 15, R29 (2014).

Acknowledgements
We thank N. Otani, Y. Miyoshi for technical assistance. This work was supported by the Japan Society for the Promotion of Science KAKENHI grants (JP16H06568 and JP18H02542 to T.H.); Takeda Science Foundation, Uehara Memorial Foundation of Life Science, SENSHiN medical research foundation, and the International Collaborative Research Program of Institute for Protein Research, Osaka University, ICRA-19-03 (T.H.); Stanley, S-R, RUSK, NARSAD, and the National Institute of Health (MH-094268 Silvio O. Conte Center, MH-105660, MH-107730, and DA-040127) (A.S.); and partly supported by Takeda Pharmaceutical Company Limited.

Author contributions
T.H. and A.S. designed the project. T.H., A.F. and M.M. performed experiments. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data. T.H., S.Y., T.M., A.F., M.M., H.K., K.H., T.A. and H.T. analysed data.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-58711-2.
Correspondence and requests for materials should be addressed to T.H.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2020